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Inhibition of pulmonary nuclear factor kappa-B
decreases the severity of acute Escherichia coli
pneumonia but worsens prolonged pneumonia
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Abstract
Introduction: Nuclear factor (NF)-B is central to the pathogenesis of inflammation in acute lung injury, but also
to inflammation resolution and repair. We wished to determine whether overexpression of the NF-B inhibitor
IBa could modulate the severity of acute and prolonged pneumonia-induced lung injury in a series of
prospective randomized animal studies.
Methods: Adult male Sprague-Dawley rats were randomized to undergo intratracheal instillation of (a) 5 × 109
adenoassociated virus (AAV) vectors encoding the IBa transgene (5 × 109 AAV-IBa); (b) 1 × 1010 AAV-IBa;
(c) 5 × 1010 AAV-IBa; or (d) vehicle alone. After intratracheal inoculation with Escherichia coli, the severity of the
lung injury was measured in one series over a 4-hour period (acute pneumonia), and in a second series after
72 hours (prolonged pneumonia). Additional experiments examined the effects of IBa and null-gene
overexpression on E. coli-induced and sham pneumonia.
Results: In acute pneumonia, IBa dose-dependently decreased lung injury, improving arterial oxygenation and
lung static compliance, reducing alveolar protein leak and histologic injury, and decreasing alveolar IL-1b
concentrations. Benefit was maximal at the intermediate (1 × 1010) IBa vector dose; however, efficacy was
diminished at the higher (5 × 1010) IBa vector dose. In contrast, IBa worsened prolonged pneumonia-induced
lung injury, increased lung bacterial load, decreased lung compliance, and delayed resolution of the acute
inflammatory response.
Conclusions: Inhibition of pulmonary NF-B activity reduces early pneumonia-induced injury, but worsens injury
and bacterial load during prolonged pneumonia.
Keywords: Acute lung injury, inhibitory kappa-B alpha, rat, acute respiratory distress syndrome, bacteria, pneumo-
nia, gene therapy
Introduction
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are life-threatening disorders, for
which no specific therapy is known. When ARDS occurs
in the setting of multisystem organ failure, mortality
rates more than 60% have been reported, with signifi-
cant morbidity in 50% of survivors [1]. ALI and ARDS
develop most commonly in the context of severe sepsis
[2], particularly infection with gram-negative bacilli such
as Escherichia coli (E. coli) [3], and sepsis-induced
ARDS has the worst outcome [4].
Nuclear factor kappa B (NF-B) is a key transcriptional
regulator in the setting of inflammation and injury and
plays a role in diverse inflammatory disorders, including
acute lung injury [5]. Activation of NF-B occurs in
response to diverse stimuli, such as endotoxin, which bind
to cell-surface receptors that in turn activate the canonic
and/or noncanonic signaling pathway. This signaling cas-
cade ultimately results in the phosphorylation and inacti-
vation of the cytosolic inhibitor IB complex, which then
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dissociates, allowing NF-B to translocate to the nucleus
to initiate gene transcription [5]. Inhibition of NF-B
reduces injury in preclinical models of ALI, including
ischemia-reperfusion [6], endotoxemia [7], and cecal liga-
tion and puncture-induced sepsis [8]. However, NF-B
also exerts important cytoprotective effects, promoting cell
survival, resolution of inflammation, and wound repair [9].
Of interest, NF-B signaling plays a central role in the
host response to lung bacterial infection [10]. Conse-
quently, inhibition of NF-B may constitute a double-
edged sword, particularly in pneumonia-induced ALI/
ARDS, in which immune competence is essential to eradi-
cation of the infectious agent [11].
We wished to determine the potential for inhibition of
pulmonary NF-B activity to modulate the severity of
pneumonia-induced lung injury. We used a gene-based
therapy approach, via intrapulmonary delivery of three dif-
ferent doses of adenoassociated viral vector encoding the
NF-B inhibitor IBa gene (AAV-IBa), to modulate the
NF-B signaling pathway in the lung. We hypothesized
that pulmonary overexpression of the NF-B inhibitor
IBa would (a) attenuate the severity of the lung injury
induced by acute E. coli pneumonia; but would (b) worsen
the severity of prolonged E. coli pneumonia-induced lung
injury; and (c) a dose-response relation would exist, with
higher AAV-IBa doses having the greatest effect.
Materials and methods
Specific-pathogen-free adult male Sprague-Dawley rats
(350 to 450 g) were used in all studies. The experimental
model was based on those previously reported [12-14]. All
work was approved by the National University of Ireland
Galway Research Ethics Committee and conducted under
license from the Department of Health, Ireland.
Preparation of AAV vectors
AAV-vector production was carried out as previously
described, with several modifications [15]. The IBa-
SuperRepressor (IBa-SR) gene (1,566 bp) was ligated
into the pAAV-MCS vector (Agilent Technologies Inc.,
Santa Clara, CA, USA), and plasmid size confirmed by
gel electrophoresis and validated by sequencing (Eurofins
MWG Operon, Ebersberg, Germany). The IBa-FLAG
plasmid DNA and AAV serotype 6 envelope were gener-
ated and sent to Virapur for AAV production (VIRAPUR,
6160 Lusk Blvd., Suite C-101, San Diego, CA, USA). AAV
serotype 6 was chosen because AAV has reduced immu-
nogenicity, the virus plasmid size is sufficient for the
IBa-SuperRepressor (IBa-SR) gene, and serotype 6 has
demonstrated tropism for lung epithelial cells.
Viral vector particle titers were determined with quan-
titative real-time polymerase chain reaction (qRT-PCR)
and aliquoted and stored at -80oC. As required, an ali-
quot was thawed and added to 75 μl of the porcine
surfactant Curosurf (120 mg/ml) (Trinity-Chiesi Phar-
maceuticals Limited, Cheadle, UK), and a final instillate
volume of 300 μl was made up with PBS. For those ani-
mals receiving vehicle only, the instillate was 75 μl of
Curosurf mixed with 225 µl of phosphate-buffered saline
(PBS). Curosurf surfactant was added to each instillate,
as it was demonstrated in prior studies to enhance
spread and improve transgene expression [16].
Acute and prolonged E. coli-induced lung injury
Experimental design
Animals were randomized to intratracheal instillation of
the following: (a) vehicle alone; (b) 5 × 109 drp AAV
IBa-SR; (c) 1 × 1010 drp AAV IBa-SR; or (d) 5 × 1010
drp AAV IBa-SR, and to undergo subsequent acute
(Series 1) or prolonged (Series 2) pneumonia-induced
ALI. Additional experimental series examined the effects
of 1 × 1010 AAV-IBa versus 1 × 1010 AAV-Null in
both acute and prolonged E. coli and sham pneumonia.
Vector instillation
Animals were anesthetized by inhalational induction with
isoflurane and an intraperitoneal injection of 40 mg/kg
ketamine (Pfizer, Kent, UK). After confirmation of depth
of anesthesia, laryngoscopy was performed (Welch Allyn
Otoscope; Buckinghamshire, UK), and the trachea intu-
bated with a size 16 intravenous catheter (BD Insyte;
Becton Dickinson Ltd., Oxford, UK). After instillation of
vector or vehicle, depending on the specific series, animals
were extubated and allowed to recover from anesthesia.
E. coli/vehicle instillation
The E. coli used in these experiments is E5162 (serotype:
O9 K30 H10) and was supplied by the National Collection
of Type Cultures, Central Public Health Laboratory, Lon-
don, England. The E. coli were stored on preservative
beads (Protect, Lancashire, England) at -80°C. Beads were
placed in 3-ml vials of peptone water (Cruinn Diagnostics,
Dublin, Ireland) and incubated at 37°C for 18 to 24 hours
to allow bacterial concentrations to reach a plateau. The
bacterial suspension was then centrifuged and washed in
phosphate-buffered saline to produce the inoculum. The
bacterial load in each inoculum was determined by plating
serial dilutions on agar plates. Preliminary experiments
were performed to determine the bacterial load of intratra-
cheal E. coli required to produce a lung injury over a
4-hour and over a 72-hour period.
Acute pneumonia protocol
Ninety-six hours after virus instillation, animals were
anesthetized with intraperitoneal 80 mg/kg ketamine and
8 mg/kg xylazine, and anesthesia maintained with Alfaxa-
lone (Alfaxadone 0.9% and alfadadolone acetate 0.3%).
A tracheostomy tube was inserted, and intraarterial access
was sited in the carotid artery. Muscle relaxation was
induced with cisatracurium besylate, and the lungs were
mechanically ventilated with 30% O2 in 70% N2. After
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20 minutes, arterial blood gas measurement was per-
formed and 1 × 1011 E. coli in a 300-μl PBS suspension (or
vehicle alone) instilled via the tracheostomy [12,13].
Animals were ventilated for 4 hours, with systemic arterial
blood pressure, peak airway pressure, and body tempera-
ture continually measured. Lung compliance and arterial
blood gas analysis was measured hourly, and body tem-
perature was maintained at 36°C to 37.5°C.
Prolonged pneumonia protocol
Animals were anesthetized by inhalational induction
with isoflurane and intraperitoneal 40-mg/kg ketamine
(Pfizer, Kent, UK). After confirmation of anesthesia
depth, 5 × 109 E. coli in a 300-μl PBS suspension was
instilled into the trachea under direct vision, and the
animals allowed to recover [17]. Animals were moni-
tored closely for 72 hours after E. coli instillation, and
then reanesthetized, tracheostomized, and mechanical
ventilation was instituted, and injury severity assessed,
as described [18].
Postmortem analyses
At the end of the protocols, the animals were killed by
exsanguination under anesthesia, and the plasma snap-
frozen for later analysis. The heart-lung block was dis-
sected from the thorax, bronchoalveolar lavage (BAL)
was performed, and BAL fluid differential leukocyte
counts and lung bacterial colony counts were completed.
BAL fluid was centrifuged, and the supernatant was
snap-frozen and stored at -80°C. BAL concentrations of
IL-1b, TNF-a, IL-6, CINC-1, IL-10, and KGF were deter-
mined by using ELISA (R&D Systems, Abingdon, UK),
and BAL protein concentrations were measured (Micro
BCA Protein assay kit; Pierce, Rockford, IL, USA) [16].
The left lung was isolated and fixed, and the extent of
histologic lung damage determined by using quantitative
stereologic techniques [18].
Assessment of transgene expression and efficacy
IBa-FLAG transgene expression was determined in
lung homogenates with real-time PCR and Western
blotting, as previously described [16,19]. In brief, RNA
was extracted from lung tissue, cDNA was synthesised,
and quantitative PCR was performed for IBa-FLAG,
normalized against a GAPDH control product. For Wes-
tern blot IBa-FLAG analysis, total cell protein was
extracted, protein concentration was determined, and
samples were electrophoresed on an SDS-PAGE gel and
transferred to nitrocellulose [20]. Primary anti-human
IBa-FLAG monoclonal antibody (Sigma-Aldrich, St.
Louis, MO, USA) was used, with secondary antibody
conjugated to horseradish peroxidase (Cell Signaling
Technology, Danvers, MA, USA), and the membrane
incubated with a chemiluminescent substrate (Super-
Signal West Pico; Pierce).
The effect of IBa overexpression on the activation of
the NF-B pathway was assessed by measurement
of nuclear accumulation of the activated P65 subunit of
NF-B [19]. Nuclear extracts were performed on homo-
genized rat lung tissue by using a NE-PER Nuclear and
Cytoplasmic Extraction Kit (Fisher Scientific Ireland,
Dublin, Ireland), and NF-B (p65) measured by using
an NF-B Transcription Factor Assay Kit (Cayman Che-
mical Company, Ann Arbor, MI, USA).
Data presentation and analysis
Continuous responsive variables are summarized by
using mean (SD) and median (interquartile range, IQR)
as necessary. The proportion of animals surviving was
analyzed by using the c2 test. All other data were ana-
lyzed with one-way ANOVA, followed by the Dunnett
test or by Kruskal-Wallis, followed by the Dunn test,
with the vehicle group used as the reference group for
all comparisons. The assumptions underlying all models
were checked by using suitable residual plots. A P value
of <0.05 was considered statistically significant.
Results
Acute pneumonia-induced ALI
Sixty-eight animals were entered into these experimental
series. In the first set of experiments, 48 animals were
randomized to receive (a) vehicle alone (n = 12); (b) 5 ×
109 AAV-IBa n = 12); (c) 1 × 1010 AAV-IBa (n =
12); (d) 5 × 1010 AAV-IBa (n = 12), and all animals
subsequently underwent intratracheal E. coli instillation.
No differences were noted between the groups at base-
line (Table 1).
IBa expression and function Pulmonary instillation
of AAV-IBa produced a dose-dependent increase in
lung IBa gene transcription (Figure 1A) and protein
production (Figure 1B, C). Densitometry of IBa-FLAG
Western blot (n = 3 per group) confirmed this dose-
dependent increase in IBa protein (Figure 1C). IBa
overexpression decreased E. coli-induced NF-B activa-
tion, as measured by nuclear accumulation of the acti-
vated P65 subunit of NF-B (Figure 1D).
Survival and bacterial load IBa overexpression
enhanced animal survival, with survival rates of 33% in
the Vehicle group, 58% with 5 × 109 IBa, and 92%
with 1 × 1010 IBa Of concern, the highest IBa (5 ×
1010) dose abolished the survival benefit (Table 1). IBa
overexpression also enhanced the duration of animal
survival, which followed this same pattern, with the
effect greatest with the1 × 1010 IBa dose (Table 1).
Importantly, IBa did not alter lung bacterial loads
(Table 1).
IBa modulated lung-injury severity
The E. coli instillation induced a severe acute lung
injury (Figure 2). IBa overexpression reduced the
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Table 1 Data regarding animals subjected to acute pneumonia-induced ALI
Variable Vehicle 5 × 109 IBa 1 × 1010 IBa 5 × 1010 IBa
Number of animals 12 12 12 12
Animal weight (g) 456 ± 55 486 ± 54 469 ± 52 438 ± 86
Bacteria instilled (CFU × 1010) 1.1 ± 0.2 2.1 ± 0.2 2.6 ± 2.0 2.1 ± 2.2
Baseline arterial PO2 (kPa) 18.7 ± 0.5 18.7 ± 0.8 18.8 ± 0.8 18.7 ± 0.8
Baseline static compliance (ml/mm Hg) 0.93 ± 0.1 0.95 ± 0.1 0.99 ± 0.2 0.87 ± 0.2
Animal survival (number, %) 4 (33) 7 (58) 11 (92)* 5 (42)
Duration of animal survival (hours) 2.75(2, 4) 4 (1.5, 4) 4 (4, 4)* 3 (1.75, 4)
Lung homogenate bacterial counts (CFU × 109) 0.8 (0.4, 1.7) 1.4 (0.2, 2.6) 0.6 (0.4, 0.9) 0.7 (0.4, 0.9)
BAL neutrophils (× 107/ml) 5.9 (1.5, 8.4) 3.7 (1.5, 8.9) 6.2 (1.8, 6.7) 8.5 (1.1, 9.1)
BAL mononuclear cells (× 107/ml) 2.2 (1.4, 9.1) 0.57 (2.7, 7.0) 1.5 (1.2, 9.3) 1.8 (1.1, 9.6)
Note: Data are expressed as mean ± SD. *Significantly different from Vehicle group.
Figure 1 Overexpression of IBa-reduced NF-B activity. Delivery of the adeno-associated viral vector encoding IBb resulted in a dose-
dependent increase in lung homogenate IBb FLAG mRNA expression (A) and IBb protein concentrations, as demonstrated by the
representative Western blot (B), and by densitometry of Western blots (n = 3 per group) (C). IBb decreased Escherichia coli-induced nuclear
accumulation of the activated P65 subunit of NF-B (D). Vehicle, animals that received intratracheal vehicle alone; IBb 5 × 109, animals that
received 5 × 109 AAV6 particles encoding IBb; IBb 1 × 1010, animals that received 1 × 1010 AAV6 particles encoding IBb; IBb 5 × 1010,
animals that received 5 × 1010 AAV6 particles encoding IBb. *Significantly different from vehicle group (P < 0.05, ANOVA).
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E. coli-induced decrement in arterial oxygenation, with
benefit greatest at intermediate (1 × 1010) IBa vector
dose, but abolished at the higher (5 × 1010) IBa dose
(Figure 2A and Table 1). A similar pattern was seen
with regard to the decrement in static compliance
(Figure 2B), and pulmonary permeability, as assessed by
protein leak into the BAL fluid (Figure 2C), but no
effect was seen in regard to BAL neutrophil or mono-
nuclear cell counts (Figure 2D and Table 1). IBa
reduced E. coli-induced histologic evidence of lung
injury, with the intermediate (1 × 1010) vector dose of
IBa again most effective (Figure 3A through E).
IBa modulates pulmonary inflammation
The E. coli instillation activated the inflammatory
response. IBa significantly decreased alveolar IL-1b,
but did not alter BAL TNF-a or interleukin-6 concen-
trations (Figure 4A through C). IBa dose-dependently
modulated BAL CINC-1 and KGF, but did not alter
BAL IL-10 concentrations (Figure 4D, F).
Sham acute pneumonia and null-transgene series
Additional experiments were performed to determine the
effect of overexpression of a null transgene (versus vehicle;
n = 4 per group) on the severity of E. coli pneumonia, and
to determine the effect of IBa and null-gene overexpres-
sion in sham pneumonia (versus vehicle; n = 4 per group).
In these studies, the null transgene did not alter the sever-
ity of E. coli-induced lung injury (Table 2). In addition,
overexpression the null or IBa transgenes in sham-
injured animals did not alter lung function (Table 3).
Figure 2 IBa modulated severity of acute pneumonia-induced ALI. Overexpression of IBa attenuated the decrement in arterial
oxygenation (A), and in static lung compliance (B), and decreased BAL protein concentrations (C), after Escherichia coli-induced ALI. Beneficial
effects were greatest with the intermediate IBa (1 × 1010 particles) dose but were abolished by the higher IBa (5 × 1010 particles) dose. No
effect of IBa was noted on BAL neutrophil infiltration (D). The gray bars represent sham (that is, uninfected) animals. Vehicle, animals that
received intratracheal vehicle alone; IBa 5 × 109, animals that received 5 × 109 AAV6 particles encoding IBa; IBa 1 × 1010, animals that
received 1 × 1010 AAV6 particles encoding IBa; IBa 5 × 1010, animals that received 5 × 1010 AAV6 particles encoding IBa. Significantly
different from vehicle group (P < 0.05, ANOVA).
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Figure 3 IBa modulated structural lung injury induced by acute pneumonia. Overexpression of IBa attenuated the decrement in
alveolar airspace and the increase in alveolar tissue (A) after pneumonia-induced lung injury. (B) Image from a pneumonia-injured lung that
received intratracheal vehicle, demonstrating increased wall thickness and inflammatory cell infiltrate. (C through E) Images from pneumonia-
injured lungs that received increasing doses of intratracheal vector encoding the IBa transgene. The animals that received the intermediate
(5 × 1010) dose demonstrated reduced injury and inflammatory cell infiltration. Vehicle, animals that received intratracheal vehicle alone; IBa
5 × 109, animals that received 5 × 109 AAV6 particles encoding IBa; IBa 1 × 1010, animals that received 1 × 1010 AAV6 particles encoding
IBa; IBa 5 × 1010, animals that received 5 × 1010 AAV6 particles encoding IBa. Significantly different from vehicle group (P < 0.05, ANOVA).
Scale bar, 200 μm.
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Figure 4 IBa dose-dependently modulated the inflammatory response to acute pneumonia-induced ALI. Overexpression of IBa
attenuated the increase in BAL interleukin-1b (A), but did not alter BAL TNF-a (B), or interleukin-6 concentrations (C), after Escherichia coli-
induced ALI. IBa dose dependently decreased BAL CINC-1 (D), did not alter BAL IL-10 concentrations (E), and dose dependently decreased BAL
KGF concentrations (F). These effects were greatest with the highest IBa (5 × 1010 particles) dose. The gray bars represent sham (uninfected)
animals. Vehicle, animals that received intratracheal vehicle alone; IBa 5 × 109, animals that received 5 × 109 AAV6 particles encoding IBa;
IBa 1 × 1010, animals that received 1 × 1010 AAV6 particles encoding IBa; IBa 5 × 1010, animals that received 5 × 10109 AAV6 particles
encoding IBa, BAL, bronchoalveolar lavage; IL-1b, interleukin-1b; TNF-a, tumor necrosis factor-a; CINC-1, cytokine-induced neutrophil
chemoattractant-1; KGF, keratinocyte growth factor. Significantly different from vehicle group (P < 0.05, ANOVA).
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Prolonged pneumonia-induced ALI
Fifty-six animals were entered into these experimental
series. In the first set of experiments, 44 animals were
randomized to receive (a) vehicle (n = 11); (b) 5 × 109
AAV-IBa (n = 11); (c) 1 × 1010 AAV-IBa (n = 11);
(d) 5 × 1010 AAV-IBa (n = 11), and underwent pro-
longed E. coli-induced lung injury. No differences were
found between the groups at baseline (Table 4).
Animal Survival and Bacterial Load
IBa did not alter the number or duration of animal survi-
val (Table 4). However, IBa substantially increased lung
E. coli bacterial loads at all three IBa doses (Table 4).
IBa worsens lung injury
E. coli instillation induced a severe lung injury compared
with sham pneumonia (Figure 5). IBa overexpression
did not alter the decrement in arterial oxygenation
(Figure 5A). IBa overexpression dose dependently wor-
sened static lung compliance (Figure 5B). IBa did not
alter alveolar protein leak (Figure 5C), but did increase
the proportion of neutrophils in the alveolar infiltrate
(Figure 5D), while decreasing alveolar mononuclear cells
(Table 4). IBa worsened E. coli-induced histologic
injury, with the intermediate (1 × 1010) and higher (5 ×
1010) dose of IBa, resulting in significantly greater
injury (Figure 6A through E).
IBa modulates pulmonary inflammation
Prolonged E. coli pneumonia activated the inflammatory
response compared with sham pneumonia (Figure 7).
IBa overexpression dose-dependently increased alveo-
lar IL-1b (Figure 7A) and TNF-a (Figure 7B), with con-
centrations highest after 5 × 1010 IBa. In contrast, no
effect was seen on alveolar IL-6 (Figure 7C) or CINC-1
(Figure 7D) concentrations. IBa increased alveolar IL-
10 (Figure 7E) and KGF concentrations, with a step-wise
dose effect seen (Figure 7F).
Sham Prolonged Pneumonia
In a subsequent experiment, 12 animals were randomized
to receive: (a) Vehicle (n = 4); (b) 1 × 1010 AAV-Null (n =
4); and (3) 1 × 1010 AAV-IBa and to undergo subsequent
Table 2 Overexpression of Null transgene does not modulate the severity of acute pneumonia-induced ALI
Variable E. coli + vehicle E. coli + null transgene
Number of animals 4 4
Animal weight (g) 443 ± 25 462 ± 33
Bacteria instilled (CFU × 1010) 1.1(0.9, 1.2) 1.2(0.5, 3.6)
Animal survival (n, %) 2 (50%) 2 (50%)
Duration of animal survival (hours) 3.5(2, 4) 3.75 (2.5, 4)
Lung homogenate bacterial counts (CFU × 109) 1.7 (1.4, 3.8) 2.2 (1.2, 3.7)
Final arterial PO2 (kPa) 10.8 ± 0.8 9.3 ± 1.2
Final static compliance (ml/mm Hg) 0.39 ± 0.1 0.39 ± 0.1
BAL protein (mg/L) 7,203 (5,319, 7,646) 5,542 (2,994, 8,554)
BAL neutrophils (× 107/ml) 3.8 (2.1, 5.2) 8.1 (4.6, 11.2)
BAL mononuclear cells (× 107/ml) 0.88 (0.13, 0.72) 1.2 (0.18, 2.0)
Data are expressed as mean ± SD or median (interquartile range). Final data are data collected on completion of the experimental protocol. *Significantly
different from Vehicle group. BAL, bronchoalveolar lavage; CFU, colony-forming unit.
Table 3 Overexpression of Null or IBa transgenes does not alter lung function in animals subjected to sham
pneumonia
Variable Vehicle IBa transgene Null transgene
Number of animals 4 4 4
Animal weight (g) 413 ± 30 426 ± 17 427 ± 19
Animal survival (n, %) 4 (100%) 4 (100%) 4 (100%)
Duration of animal survival (hours) 4 [4,4] 4 [4,4] 4 [4,4]
Final arterial PO2 (kPa) 18.6 ± 0.5 18.4 ± 1.1 19.9 ± 0.7
Final static compliance (ml/mm Hg) 0.65 ± 0.11 0.71 ± 0.17 0.58 ± 0.16
BAL protein (mg/L) 1197 [1061, 1296] 1353 [991, 2167] 1337 [950, 1869]
BAL neutrophils (× 104/ml) 0.2 [0.0, 1.4] 1.3 [0.5, 1.8] 1.1 [0.2, 2.0]
BAL mononuclear cells (× 104/ml) 21.0 [11, 22] 23 [10, 29] 14 [12, 18]
Data are expressed as mean ± SD or median (interquartile range). Final data are data collected on completion of the experimental protocol. *Significantly
different from Vehicle group. BAL, bronchoalveolar lavage; CFU, colony-forming units.
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Table 4 Data regarding animals subjected to prolonged pneumonia-induced ALI
Variable Vehicle 5 × 109 IBa 1 × 1010 IBa 5 × 1010 IBa
Number of animals 11 11 11 11
Animal weight (g) 383 ± 13 378 ± 19 413 ± 35 401 ± 47
Animal survival (number, %) 8 (73) 9 (82) 9 (82) 8 (73)
Duration of animal survival (hours) 65.5 ± 11.2 64.8 ± 16.2 63.3 ± 19.4 63.3 ± 16.1
Instilled E. coli bacterial load (CFU × 104) 5.0 ± 1.0 5.0 ± 1.0 5.0 ± 1.0 5.0 ± 1.0
Peak airway pressure (mm Hg) 8.1 ± 1.4 6.5 ± 1.0 7.4 ± 1.0 8.0 ± 1.3
Lung homogenate bacterial counts (CFU × 104) 1.1 (0.7, 3.1) 51.3 (3.1, 96)* 20.7 (15.9, 36.2)* 19.3 (16.5, 34.6)*
BAL neutrophils (× 109/ml) 3.7 ± 3.3 2.3 ± 0.8 3.8 ± 2.2 1.7 ± 0.9
BAL mononuclear cells (× 109/ml) 2.3 ± 1.8 0.4 ± 0.2* 0.9 ± 0.6* 0.4 ± 0.2*
Data are expressed as mean ± SD or median (interquartile range). Final data are data collected on completion of the experimental protocol. *Significantly
different from Vehicle group. BAL, bronchoalveolar lavage; CFU, colony-forming units.
Figure 5 IBa worsened ALI induced by prolonged pneumonia. Overexpression of IBa did not alter the decrement in arterial oxygenation
(A). IBa worsened the Escherichia coli-induced decrement in static lung compliance, with effect greatest with 5 × 1010 IBa particles (B). IBa
did not alter BAL protein concentrations (C), but did significantly increase the percentage of neutrophils in the alveolar infiltrate (D). The gray
bars represent sham (uninfected) animals. Vehicle, animals that received intratracheal vehicle alone; IBa 5 × 109, animals that received 5 × 109
AAV6 particles encoding IBa; IBa 1 × 1010, animals that received 1 × 1010 AAV6 particles encoding IBa; IBa 5 × 1010, animals that received
5 × 1010 AAV6 particles encoding IBa. Significantly different from vehicle group (P < 0.05, ANOVA).
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Figure 6 IBa worsened structural lung injury induced by prolonged pneumonia. Overexpression of IBa worsened the decrement in
alveolar airspace and the increase in alveolar tissue (A) after pneumonia-induced lung injury. (B) Image from a prolonged pneumonia-injured
lung that received intratracheal vehicle, demonstrating increased wall thickness and inflammatory cell infiltrate. (C through E) Images from a
pneumonia-injured lung that received increasing doses of intratracheal vector encoding the IBa transgene. The animals that received 1 to 5 ×
1010 doses demonstrated greater injury. Vehicle, animals that received intratracheal vehicle alone; IBa 5 × 109, animals that received 5 × 109
AAV6 particles encoding IBa; IBa 1 × 1010, animals that received 1 × 1010 AAV6 particles encoding IBa; IBa 5 × 1010, animals that received
5 × 1010 AAV6 particles encoding IBa. *Significantly different from vehicle group (P < 0.05, ANOVA). Scale bar, 200 μm.
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Figure 7 IBa dose-dependently modulated the inflammatory response to prolonged pneumonia. Overexpression of IBa dose-
dependently increased BAL interleukin-1b (A) and TNF-a (B) concentrations compared with vehicle. No effect of IBa was seen on interleukin-6
(C) or CINC-1 (D) concentrations. IBa dose-dependently increased BAL IL-10 (E), and KGF concentrations (F). These effects were greatest with
the highest IBa (5 × 1010 particles) dose. The gray bars represent sham (uninfected) animals. Vehicle, animals that received intratracheal vehicle
alone; IBa 5 × 109, animals that received 5 × 109 AAV6 particles encoding IBa; IBa 1 × 1010, animals that received 1 × 1010 AAV6 particles
encoding IBa; IBa 5 × 1010, animals that received 5 × 1010 AAV6 particles encoding IBa. *Significantly different from vehicle group (P < 0.05,
ANOVA).
Devaney et al. Critical Care 2013, 17:R82
http://ccforum.com/content/17/2/R82
Page 11 of 15
sham (vehicle) instillation. The null or IBa transgenes
did not alter lung function in sham infected animals
(Table 5).
Discussion
Pulmonary overexpression of IBa attenuated acute pneu-
monia-induced lung injury, decreasing the severity of the
decrement in lung function, whereas also decreasing the
inflammatory response. In contrast, IBa worsened lung
injury and inflammation induced by prolonged pneumonia,
increasing lung bacterial load and delaying resolution of
the inflammatory response. These findings provide novel
insights into the effects of NF-B in pneumonia-induced
lung injury, and raise concerns regarding therapeutic
potential of inhibiting NF-B, particularly in prolonged
untreated pneumonia.
E. coli acute and prolonged pneumonia
Infection with gram-negative bacilli such as E. coli is the
commonest cause of ARDS [21,22] and is also a very
common complication of ARDS due to other causes
[23]. We studied E. coli-induced pneumonia, a well-
characterized animal model that mimics the clinical
development of ARDS very closely [23-28]. Intratracheal
instillation of 1 × 1011 E. coli resulted in physiological
and pathologic changes consistent with a severe lung
injury over a 6-hour period, similar to that previously
reported [12,13]. Instillation of a lower dose of 5 × 109
E. coli produced a more gradually evolving injury over a
72-hour period, as previously described [14,17].
NF-B: role in lung inflammation
The role of the NF-B signaling in the host immune
response to lung injury is increasingly well understood
[19]. NF-B activation pathway gene polymorphisms
alter the susceptibility to [29] and severity [30] of clini-
cal ARDS. NF-B is a dimer of a number of related pro-
teins, including RelA (also known as P65), p50, p52,
RelB, and cRel, with the RelA and p50 heterodimer, the
most common form. On cell activation, by stimuli such
as gram-negative bacterial endotoxin, diverse signaling
pathways are activated, which converge to phosphorylate
and activate the IB kinase complex proteins (IKK),
which then phosphorylate and inactivate the IB pro-
teins, which dissociates from NF-B. The active NF-B
translocates to the nucleus and binds to specific cognate-
binding sequences in the promoter or enhancer regions
of different target genes to initiate transcription [5].
The therapeutic potential of strategies to inhibit NF-B
is evident from the demonstration that NF-B inhibition
decreases injury in nonseptic ALI models, including pul-
monary [6] and systemic reperfusion, and endotoxemia
[7]. Pulmonary overexpression of the RelB member of
the NF-B family decreases cigarette smoke-induced
lung injury [31].
ARDS, pneumonia, and NF-B
The effects of modulation of the NF-B in the setting of
lung bacterial infection are less well understood [19].
NF-B decoy oligodeoxynucleotides reduce ALI in mice in
the early phases of cecal ligation and puncture-induced
sepsis [8]. Selective inhibition of vascular endothelial
NF-B activity in endotoxemic transgenic mice reduced
lung inflammation and increased survival [32]. Of interest,
this approach improved survival and systemic organ func-
tion, but did not alter bacterial clearance, in septic mice
[32]. However, others have found inhibition of NF-B sig-
naling to exert detrimental effects in the setting of infec-
tion. Inhibition of hepatocyte NF-B activity reduced
Listeria monocytogenes clearance, decreasing murine survi-
val [11]. In contrast, clearance of pseudomonas bacteria
from the mouse lung was enhanced by pulmonary overex-
pression of the RelA subunit of NF-B [33], suggesting
that the NF-B pathway plays a pivotal role in maintaining
immune competence and is essential to eradication of the
infectious agent [11].
Table 5 Overexpression of Null or IBa transgenes does not alter lung function or activate the immune response in
animals subjected to sham prolonged pneumonia-induced ALI
Variable Vehicle IBa transgene Null transgene
Number of animals 4 4 4
Animal weight (g) 411 ± 24 409 ± 14 395 ± 11
Animal survival (n, %) 4 (100%) 4 (100%) 4 (100%)
Duration of animal survival (hours) 72 (72, 72) 72 (72, 72) 72 (72, 72)
Final arterial PO2 (kPa) 18.3 ± 0.3 17.6 ± 2.5 18.3 ± 0.2
Final static compliance (ml/mm Hg) 0.71 ± 0.07 0.78 ± 0.09 0.75 ± 0.12
BAL protein (mg/L) 961 ± 221 829 ± 226 826 ± 180
BAL neutrophils (× 103/ml) 1.1 ± 0.7 2.2 ± 1.7 1.4 ± 1.2
BAL mononuclear cells (× 104/ml) 5.5 ± 3.6 5.2 ± 3.9 3.8 ± 2.4
Data are expressed as mean ± SD or median [interquartile range]. Final data are data collected on completion of the experimental protocol. *Significantly
different from Vehicle group. BAL, bronchoalveolar lavage; CFU, colony-forming units
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NF-B: role in lung inflammation, injury, and repair
NF-B also promotes cell survival, resolution of inflam-
mation, and repair after injury. Inhibition of NF-B sig-
naling retards pulmonary [20] and intestinal [34]
epithelial wound healing. Maturational differences in
lung NF-B activation profiles exist, with NF-B activa-
tion protecting the lung against hyperoxia [35] and
endotoxemia [36] in neonatal rats. Consequently strate-
gies to inhibit NF-B, particularly if not spatially or
temporally targeted, may have detrimental effects.
Targeting pulmonary NF-B
We wished to determine whether inhibition of pulmonary
NF-B activity could modulate the severity of pneumonia-
induced lung injury. We found that pulmonary overexpres-
sion of the IBa gene did reduce acute pneumonia-induced
injury. IBa decreased the decrement in arterial oxygena-
tion and lung static compliance, decreased alveolar protein
leak, and decreased histologic injury, compared with vehi-
cle. IBa modulated the cytokine response to E. coli instil-
lation, decreasing alveolar IL-1b but increasing CINC-1
concentrations. Of importance, these effects were dose
dependent, with benefit maximal at the intermediate (1 ×
1010) IBa dose, and a loss of efficacy at the higher (1 ×
1010) IBa concentration.
In contrast, in prolonged untreated E. coli pneumonia,
pulmonary IBa gene overexpression worsened the lung
injury, and increased lung bacterial load. IBa delayed the
resolution of the acute inflammatory response, increasing
the proportion of alveolar neutrophils while decreasing
alveolar mononuclear cells, which comprise lymphocytes
and macrophages and are considered important to repair.
IBa increased alveolar concentrations of TNF-a and IL-
1b, cytokines implicated in the early phase of the response
to septic insult. IBa increased alveolar IL-10 concentra-
tions, which may partly explain the ineffective response to
the bacterial insult.
NF-B and sepsis: an integrated paradigm
The contrasting effects of NF-B inhibition in acute versus
prolonged pneumonia generate a number of important
insights. First, the finding that NF-B inhibition reduced
the severity of acute pneumonia and decreased the host
response induced ALI suggests that any benefit in this set-
ting is mediated via a decreased host response to the instil-
lation of E. coli [37]. This is consistent with the concept
that in the early phases of pneumonia, secreted toxins, and
the host immune response may be the predominant
source of injury [37,38]. This is supported by the fact that
NF-B inhibition is protective in nonseptic inflammatory
ALI models. Second, this effect was dose dependent, with
lower and intermediate IBa doses protective and the
beneficial effects ablated at higher doses. This suggests a
U-shaped dose-effect curve, reducing the therapeutic
utility of approaches to inhibit NF-B in the setting of
acute pneumonia. Third, IBa worsened the severity of
prolonged pneumonia, substantially increasing lung bac-
terial loads, and resulting in a persisting pulmonary
inflammatory response. IBa, by inhibiting the early host
response to E. coli instillation, may have led to a persis-
tence of infection, ultimately worsening lung injury.
Finally, the beneficial effects of NF-B inhibition in acute
pneumonia were lost at the highest dose. The reasons for
this is unclear, but may include NF-B inhibition
mediated reduction in lung epithelial repair [20], apoptosis
of airway epithelial cells [16] and effects on lung macro-
phage function [39].
Conclusions
IBa overexpression reduces injury severity and inflam-
mation in early pneumonia, but slows resolution of
inflammation and bacterial clearance and worsens injury
during prolonged pneumonia. These findings raise ser-
ious questions regarding the utility of strategies that
inhibit the innate immune response, such as NF-B, in
live bacterial pneumonia.
Key Message: Inhibition of pulmonary NF-B activity
decreases the severity of early pneumonia-induced lung
injury, but worsens injury severity and bacterial load
during prolonged pneumonia.
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